Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

Conclusion The recommended phase II dose of lurbinectedin is 5  mg, administered as a 1-h infusion on days 1 and 8 every 3 weeks. These data support further testing of this dose and schedule, particularly in soft tissue sarcoma.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research